Up and Coming
This feature highlights changes in clinical trial organizations’ personnel.
Avinash Desai has been tapped as Actinium’s new executive vice president of clinical development, operations and medical affairs. Most recently, Desai served as vice president and head of U.S. medical affairs — oncology at GlaxoSmithKline.
Acutus Medical has named Steven Mickelsen chief translational science officer of the company. Mickelsen was the former founder of FARAPULSE.
Dennis Kim has been appointed chief medical officer of AFYX Therapeutics. Prior to joining AFYX, Kim was chief medical officer of Emerald Health Sciences.
Pablo Alvarez, former commercial operations director of Almirall U.S., has been named president of the company.
Belgium-based biotechnology company Apaxen has appointed Bart Wuurman to be its CEO. Wuurman previously served as CEO of LYRAMID and currently serves as a director of Hercules Pharmaceuticals.
Aspira Women’s Health
Aspira Women’s Health has tapped Kaile Zagger as its new chief operating officer, Lesley Northrop as chief scientific officer, Elena Ratner as global chief medical adviser for clinical and translational medicine and Gary Altwerger as global deputy chief medical adviser for clinical and translational medicine. Previously, Zagger was vice president of North America at Change Healthcare. Northrop served as managing director of Laboratory Diagnostics and Genomics Innovation prior to joining Aspira Women’s Health, Ratner currently serves as professor at Yale School of Medicine, and Altwerger currently practices at several hospitals in the areas of gynecologic oncology and obstetrics and gynecology.
Nicole White has been named senior vice president of pharmaceutical development and manufacturing at Assembly Biosciences. Most recently, White headed process chemistry at Gossamer Bio.
Nick Staples has taken the helm of Avvinity Therapeutics as its interim CEO. Staples was previously CEO for Locate Bio.
Robert Honigberg, former senior medical director at Flexion Therapeutics, has been named interim chief medical officer of Caladrius Biosciences.
Celularity has named Gregory Berk the company’s new chief medical officer and Chi Li its senior vice president of regulatory affairs. Berk previously served as president and chief medical officer at Vedantra Pharmaceuticals, and Li was vice president of regulatory affairs at Allergan prior to joining Celularity.
Peter Trainer, former honorary professor of endocrinology at the University of Manchester, has been named vice president of clinical endocrinology at Crinetics Pharmaceuticals.
Taunia Markvicka has been named chief operating officer of Cytocom. Most recently, Markvicka served as chief operating officer at PolyPid.
Shawn Leland, founder and chief business officer of Elevation Oncology, has been promoted to CEO of the company.
The new executive director and chief operating officer at Eris Lifesciences is V Krishnakumar, formerly a corporate finance partner with EY India.
Flagship Pioneering has found its new chief medical officer in Luciano Rossetti, Merck’s former global head of R&D.
Faheem Hasnain has been named CEO of Gossamer Bio. Previously, Hasnain served as president and CEO of Receptos.
Lynette Hopkinson has been appointed to the role of senior vice president of regulatory at Imara. Hopkinson joints Imara from Vertex Pharmaceuticals, where she served as vice president and global head of cystic fibrosis regulatory strategy and commercial regulatory affairs.
Kevin Johnson has been named senior vice president of regulatory affairs at Inozyme Pharma. Most recently, Johnson was the senior vice president and head of regulatory and quality at Magenta Therapeutics.
KBP Biosciences has appointed Douglas Losordo to the role of chief medical officer. Formerly, Losordo was chief medical officer for Caladrius Biosciences.
Brian O’Callaghan, former CEO of Petra Pharma Corporation, has been appointed CEO of ObsEva.
ONK Therapeutics has appointed Rohit Duggal head of R&D. Duggal was previously the senior director of primary lymphocyte R&D at NantKwest.
RVL Pharmaceuticals has hired Raymond Douglas to take on the role of global head of scientific affairs. Douglas also serves as chief medical officer of Flowmetric and owns and operates a private practice in Beverly Hills.
Sensyne Health has named Derek Baird president of North America. Baird previously served as senior vice president of growth at AVIA.
Sio Gene Therapies
Guangping Gao is Sio Gene Therapies’ new chief scientific adviser for its adeno-associated virus research program. Gao is co-director of the Li Weibo Institute for Rare Disease and director of the Horae Gene Therapy Center and Viral Vector Core.
Spark Therapeutics has appointed Michael Retterath to the role of chief strategy officer. Retterath was previously a partner in the healthcare practice at Bain & Company.
Talaris Therapeutics has hired Michael Zdanowski as chief technology officer, Farah Natoli as head of portfolio and program management and Mary West as vice president of clinical operations. In their former roles, Zdanowski served as vice president of good manufacturing practice operations for the New York Stem Cell Foundation, Natoli was the executive director of program and alliance leadership at Bioverativ, and West served as clinical operations head at Alnylam Pharmaceuticals.
Talis Biomedical has appointed Rob Kelley as the company’s first chief commercial officer. Most recently, Kelley was vice president of sales and commercial development at Genalyte. Talis Biomedical also named Douglas Liu as senior vice president of operations. Liu previously served as senior vice president of global operations at QIAGEN.
Oncology research company Vor Biopharma has selected Tirtha Chakraborty as its first chief scientific officer. Before joining Vor, Chakraborty was vice president of cell therapy research at Sana Biotechnology.
Ziopharm Oncology has hired Raffaele Baffa to assume the role of chief medical officer. Baffa was formerly the head of R&D and chief medical officer of Medisix.